Menu

Pharma News

China-flag

Further collaborations formed to penetrate China’s generics market

Home/Pharma News | Posted 18/10/2019

The Chinese pharmaceutical market is the second largest in the world, and generic drugs make up 70% of its value. Continued growth of China’s generics industry is anticipated owing to rapid population ageing and government policies to promote generics [1]. It is therefore not surprising that generic drug manufacturers are keen to penetrate this market, and indeed over the last few months there have been a number of collaborations with this objective [2-4]. Most recently, Japanese drugmakers Eisai and Nichi-Iko Pharmaceutical entered into a collaboration agreement to sell generic drugs in China, while Sun Pharmaceutical Industries (Sun Pharma) partnered with China Medical System Holdings (CMS) to develop and commercialise generics in China.

138 AA011155

Celltrion contracts Lonza to manufacture autoimmune treatment Remsima

Home/Pharma News | Posted 04/10/2019

South Korean biosimilars manufacturer Celltrion have announced a deal with Swiss contract manufacturing organisation (CMO) Lonza to produce its autoimmune biosimilar Remsima at a facility in Singapore.

Cancer image015

Shanghai Pharma and Russia’s Biocad form joint venture to sell cancer and autoimmune drugs in China

Home/Pharma News | Posted 27/09/2019

Shanghai Pharmaceuticals Holding and Russia’s Biocad Pharmaceutical have agreed to form a joint venture to develop, manufacture and market cancer and autoimmune disease treatments in China.

Multiple Sclerosis V14A24

Sandoz makes deal with Polpharma for natalizumab biosimilar

Home/Pharma News | Posted 20/09/2019

Sandoz, the generics division of Novartis, and Poland-based Polpharma Biologics announced on 3 September 2019 that they had signed a worldwide agreement giving Sandoz commercialization rights to Polpharma’s candidate natalizumab biosimilar (PB006).

15 AA010699

Huons enters biosimilar market while private equity firm PAG invests in Hisun BioRay

Home/Pharma News | Posted 13/09/2019

Huons has announced its plans to enter the biosimilar market, and private equity firm PAG has acquired a controlling interesting in Hisun Pharmaceutical’s biopharmaceutical subsidiary, Hisun BioRay.

Shaking hands V13D29

Alvotech and Cipla Gulf partnership announced

Home/Pharma News | Posted 30/08/2019

On 29 July 2019, pharmaceutical companies Alvotech and Cipla Gulf announced that they have entered into an exclusive partnership for the commercialization of an adalimumab biosimilar (AVT02), in a selection of emerging markets.

Drug Shortages FDA V13K15

Agreement between Hikma and Civica to reduce US generic drug shortages

Home/Pharma News | Posted 23/08/2019

Hikma Pharmaceuticals Plc and Civica Rx announced a five-year agreement on 23 July 2019. Under the agreement, Hikma will manufacture and supply 14 essential sterile injectable medications for Civica. It will use Hikma's abbreviated new drug applications (ANDAs) and Civica's labelling and National Drug Code (NDC). The full list of medications included in the agreement, that are often in short supply in US hospitals, will be publicly announced in the near future. Initial shipments are expected by the end of 2019.

Cancer image015

WHO essential medicines list: new lung cancer medicines rejected

Home/Pharma News | Posted 16/08/2019

The World Health Organization’s (WHO) list of ‘essential medicines’, received a biennial update on 9 July 2019. It added 28 drugs but left out several new treatments for lung cancer.

19646665_l

Prestige and Pharmapark make deal for trastuzumab biosimilar

Home/Pharma News | Posted 09/08/2019

Singapore-based Prestige BioPharma (Prestige) and Russia-based Pharmapark announced on 8 July 2019 that they had signed an exclusive partnership and supply agreement for Prestige’s candidate trastuzumab biosimilar (HD201) in Russia.

Business Aquisition V13F07

Celltrion and Nan Fung Group form joint venture for copy biologicals in China

Home/Pharma News | Posted 02/08/2019

South Korean biosimilars firm Celltrion and Hong Kong-based Nan Fung Group announced on 18 July 2019 that the two companies had formed a joint venture, Vcell Healthcare, with the aim of developing and commercializing copy biologicals in China.

103 MD001949

STADA and Xbrane strengthen biosimilars collaboration

Home/Pharma News | Posted 19/07/2019

German generics giant Stada Arzneimittel (Stada) and Swedish biotech company Xbrane Bioscience (Xbrane) announced on 31 May 2019 that they have expanded their strategic biosimilar development partnership.

24-AA011041

Boehringer Ingelheim finally signs licensing deal for Humira biosimilar

Home/Pharma News | Posted 21/06/2019

Boehringer Ingelheim (Boehringer) has finally given in and signed a licensing deal for its Humira biosimilar, Cyltezo (adalimumab), in the US.

Shaking hands V13D29

Sandoz and EirGenix make deal for trastuzumab biosimilar

Home/Pharma News | Posted 07/06/2019

Sandoz, the generics division of Novartis, announced on 30 April 2019 that it had signed an agreement with Taiwan’s EirGenix to market a proposed trastuzumab biosimilar.

20893354_l

Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan

Home/Pharma News | Posted 17/05/2019

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 9 April 2019 that they had made a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar, Stelara, in Japan.

Patent 2 V13E31

Alteogen gains patent on SC trastuzumab biosimilar

Home/Pharma News | Posted 10/05/2019

South Korean biologicals company Alteogen announced on 27 March 2019 that it had gained a patent for a subcutaneous version (ALT LS2) of its candidate trastuzumab biosimilar (ALT L2).

Samsung Bioepis Engineers V16K25LB R

First Chinese biologicals maker receives EMA GMP certification

Home/Pharma News | Posted 03/05/2019

China-based WuXi Biologics announced on 20 March 2019 that it had received good manufacturing practice (GMP) certification from the European Medicines Agency (EMA).

143 AA010952

Belgian companies make biosimilars agreement

Home/Pharma News | Posted 26/04/2019

Belgian companies SYnAbs and Univercells announced on 20 April 2019 the signing of a service agreement for an undisclosed monoclonal antibody biosimilar.

129 AA010946

Celltrion has renewed success with leukaemia biosimilar Truxima and expands markets in Europe and Latin America

Home/Pharma News | Posted 19/04/2019

In recent months, South Korean biosimilars firm Celltrion has announced a series of successes, including winning a patent case against Samsung Biogen and expansions in the European and Latin American markets.

Diabetes V14K06

Novo Nordisk granted exclusivity on GLP-1 agonist Victoza until 2023

Home/Pharma News | Posted 12/04/2019

Novo Nordisk has announced a settlement with Teva Pharmaceuticals (Teva) giving the company at least four years before it has to compete with biosimilar versions of its diabetes injectable Victoza (liraglutide).

136 AA011035

AbbVie and Coherus sign licensing deal for Humira biosimilar

Home/Pharma News | Posted 05/04/2019

Coherus BioSciences (Coherus) announced in January 2019 that it had entered into global settlement agreements with AbbVie which resolve all pending disputes related to CHS-1420, Coherus’s proposed biosimilar of AbbVie’s Humira (adalimumab).

Under the terms of the settlement, Coherus will have global non-exclusive licence rights to commercialize CHS-1420 and will pay royalties to AbbVie. The licence period for CHS-1420 in the US will begin on 15 December 2023.